

OncoBRAE-GeneSGKit®

Sistemas Genómicos, which belongs to the ASCIRES biomedical group, has designed the OncoBRAE-GeneSGKit®, the most sensitive test on the market for the detection of the c.1798_1799delinsAA (p.Val600Glu) and c.1799T>A (p.Val600Lys) mutations in the *BRAF* gene, most commonly associated with **somatic melanoma and somatic colorectal cancer**, from tumour DNA, for Digital Droplet PCR platforms.

OncoBRAE-GeneSGKit® enables the detection and quantitation of the percentage of tumour DNA in a sample carrying the variants to be tested in the *BRAF* gene. The kit provides the most sensitive and specific data available on the market for the established assay conditions, with only **25 ng of tumour DNA** obtained from **fresh frozen tissue samples or samples embedded in paraffin blocks (FFPE)**, with minimal handling time.

HIGHLIGHTS

Quick and easy:


The workflow only requires final preparation of the mix for amplification by PCR, according to the number of samples to be tested, and the subsequent generation of the procedure's respective droplets. Subsequently, all that needs to be done is to perform the PCR process in the thermal cycler and to read and analyse the results obtained. Optimisation of the procedure means that results are obtained on the same working day.

Quality:

It generates reproducible and consistent results.

Optimal integration in the laboratory:

The test may be quickly incorporated into routine practice at the user's facility and readily scaled, with no need to obtain additional resources to increase the number of samples processed.



Sample preparation




Processing in ddPCR*



Analysis of results

*BioRad and Life Technologies

OncoBRAF-GeneSGKit® WORKFLOW



ABOUT US

Sistemas Genómicos (ASCIREs Group) is a leader in the use of next-generation sequencing (NGS) for genetic diagnosis. Accredited and certified under the most stringent quality standards (**ISO9001, ISO17025, ISO15189, ISO13485 and CLIA**), Sistemas Genómicos (ASCIREs Group) offers solutions for implementing and standardising NGS-based genetic diagnosis. We give professionals the **tools they need to complete the diagnostic process quickly and efficiently.**

OUR GOAL

Sistemas Genómicos (ASCIREs Group) provides **optimised diagnostic solutions**, based on state-of-the-art technology, in order to provide our customers with the necessary experience and know-how for the benefit of patients. **OncoBRAF-GeneSGKit®** enables the detection of specific treatment-related mutations in the *BRAF* gene, and the implementation of this service in laboratories, without the need to outsource the process. The results are highly reliable and the results report is generated more quickly.



DESIGN AND WORKFLOW

The OncoBRAF-GeneSGKit® working protocol is optimised for processing tumour samples, whether fresh tissue or paraffin-embedded material. The kit also contains a positive control to establish and confirm the validity of the results obtained. The technique's characteristics provide the most sensitive limits of detection and quantitation on the market.



BRAF PERFORMANCE

OncoBRAF-GeneSGKit® enables the detection and quantitation of **90% of the most significant mutations** to facilitate the **selection of the most appropriate therapy** for patients with **somatic melanoma**, and **80%** of the most significant mutations to indicate the prognosis of patients with **somatic colorectal cancer**.



CUSTOMER SUPPORT

For Sistemas Genómicos (ASCIREs Group), high-quality customer service, support and follow-up are absolutely essential. Through our adapted training programmes, we provide a **personalised service** enabling efficient implementation of NGS-based diagnosis. These programmes provide fast and simple training in the skills required to successfully and efficiently use the latest advances in sequencing technology, and to facilitate the **rapid inclusion of GeneSGKits® in routine at any laboratory.**

 GeneSGKit®

Sensitivity and specificity

cDNA	PROTEIN	FALSE POSITIVE RATE (%)	LIMIT OF DETECTION (%)	LIMIT OF QUANTITATION (%)
c.1799T>A	p.Val600Glu V600E	0.26	>0.581	>0.581
c.1798_1799delinsAA	p.Val600Glu V600K	0.26	>0.445	>0.445

References

OncoBRAF-GeneSGKit[®]: LV3800 (30 reactions) LV3802 (120 reactions)

